Clinical Trial Results:
An open label, single arm monocentric phase II study to evaluate safety,
tolerability, and preliminary efficacy of carrier-added 4-L-
[131I]iodophenylalanine
(131I-IPA), administered as sequential injections in patients
with recurrent IDH1/2 high grade glioma (HGG) concomitantly to 2nd line
external radiation therapy
Summary
|
|
EudraCT number |
2021-006426-43 |
Trial protocol |
AT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
17 Sep 2025
|
First version publication date |
17 Sep 2025
|
Other versions |
|
Summary report(s) |
IPAX_Linz_CSR_V1 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.